systematic review bpc-157 2025 BPC-157: What the Science Actually Says BPC-157: What the Evidence Actually
Description
Patients taking warfarin, heparin, DOACs (direct oral anticoagulants), or high-dose aspirin should discuss potential interactions with their provider before starting BPC-157
The evidence reality There is no robust, high-quality human outcomes literature showing that adding AOD-9604 to semaglutide or tirzepatide produces clinically meaningful additional fat loss beyond what GLP-1/GIP therapy already achieves
It is used for chronic weight management
It was the first peptide-based obesity drug to produce sustained double-digit weight loss in large randomized trials and served as the benchmark against which all newer incretin molecules are measured
&srotate=0)
